Metastatic small cell carcinoma of the endometrium: prolonged remission and possible cure following chemotherapy

1994 ◽  
Vol 4 (2) ◽  
pp. 127-130 ◽  
Author(s):  
R. W. Hunter ◽  
M. Buck ◽  
I. G. Hammond ◽  
K. E. Williams
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Advanced Disease ◽  
Neuron Specific Enolase ◽  
Complete Response ◽  
Small Cell ◽  
Response To Treatment ◽  
Short Survival ◽  
Response To Chemotherapy ◽  
Serum Neuron Specific Enolase

A 54-year-old woman with inoperable metastatic small cell carcinoma (SCC) of the endometrium was treated with cisplatin and etoposide chemotherapy on the basis of the histologic similarity to pulmonary SCC. The response to treatment was monitored using serum neuron specific enolase (NSE) levels. A complete remission was obtained with resolution of symptoms and disappearance of the mass. The patient is alive and well 4½ years later. Considering the aggressive behavior and short survival usually associated with this tumor and the presence of such advanced disease, a complete response to chemotherapy was unexpected. It would appear that chemotherapy should always be considered in the management of metastatic endometrial SCC, even in the presence of large-volume disease.

Serum Neuron-Specific Enolase as a Marker of Small-Cell Carcinoma of the Esophagus

1990 ◽  
Vol 12 (4) ◽  
pp. 384-388 ◽  
Author(s):  
Koji Sasajima ◽  
Manabu Watanabe ◽  
Toshiaki Ando ◽  
Kunihiko Hao ◽  
Masao Miyashita ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Carcinoma Of The Esophagus ◽  
Serum Neuron Specific Enolase

Treatment of Small Cell Carcinoma of the Bronchus by Combined Chemotherapy—Clinicopathological Correlation with Response

1983 ◽  
Vol 28 (3) ◽  
pp. 248-254
Author(s):  
W. MacNee ◽  
D. Maloney ◽  
D. Lamb ◽  
M. F. Sudlow
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Palliative Radiotherapy ◽  
Complete Response ◽  
Small Cell ◽  
Response To Treatment ◽  
Combined Chemotherapy ◽  
One Year ◽  
Pathological Material ◽  
The Relationship

Thirty-seven consecutive patients, referred to a respiratory unit with a histological diagnosis of small cell carcinoma of the bronchus, were treated with a combined chemotherapy regime of adriamycin, vincristine and cyclophosphamide. Palliative radiotherapy was given for the control of symptoms. Thirty of 37 patients responded to treatment, 11/37 having a complete and 19/37 a partial response. The median survival of those patients with a complete response was 55 weeks, significantly higher (P<0.01) than either those with partial or no response to treatment. Those patients with limited disease survived longer. A high proportion of patients relapsed at the primary site of the tumour in the lungs. The relationship between the therapeutic response and the histological subtype of small cell carcinoma suffered from the limitations of the available pathological material. However, more of the patients with a complete response were of the lymphocytic-like pattern of small cell carcinoma. Useful survival in these patients with inoperable small cell carcinoma was achieved using this regime of chemotherapy, even in those patients with extensive disease, five of whom had survived for over one year.

Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder

2016 ◽  
Vol 35 (1) ◽  
pp. 97-103
Author(s):  
Akihiro Naito ◽  
Satoru Taguchi ◽  
Tohru Nakagawa ◽  
Akihiko Matsumoto ◽  
Yasushi Nagase ◽  
...  
Keyword(s):  
Urinary Bladder ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Prognostic Significance ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Serum Neuron Specific Enolase

Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.

1984 ◽  
Vol 2 (4) ◽  
pp. 294-304 ◽  
Author(s):  
R Feld ◽  
W K Evans ◽  
G DeBoer ◽  
I C Quirt ◽  
F A Shepherd ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Induction Therapy ◽  
Complete Response ◽  
Cranial Irradiation ◽  
Prophylactic Cranial Irradiation ◽  
Small Cell ◽  
Response To Treatment ◽  
Maintenance Chemotherapy ◽  
Survival Times

One hundred fifty-three patients with limited and 167 with extensive small cell carcinoma of the lung (SCCL) were evaluable for response to treatment with six courses of chemotherapy (cyclophosphamide, doxorubicin, and vincristine), irradiation to intrathoracic disease, and prophylactic cranial irradiation (PCI). No maintenance chemotherapy was given. Fifty-two percent of patients with limited disease (LD) and 10% of extensive disease patients (ED) achieved a complete response. The median survival times for LD and ED patients were 49 and 34 weeks, respectively. These results were compared to a previous experience with 147 patients who were treated with three courses of similar induction chemotherapy and thoracic irradiation, as well as one year of maintenance chemotherapy (CCNU, procarbazine, and methotrexate) but without PCI. Although the use of PCI was found to reduce the frequency of brain metastases as the site of first relapse, detailed comparisons of response rates and survival showed no significant differences between the two study populations. Prolonged maintenance chemotherapy of the type used in the first study does not favorably influence outcome after intensive induction therapy for SCCL.

scholarly journals Case of metastatic small cell carcinoma of the oropharynx successfully treated with image-guided volumetric modulated arc therapy (IG-VMAT): pushing the limits of technology to match treatment intent

2018 ◽  
Vol 11 (1) ◽  
pp. bcr-2018-226522
Author(s):  
Irfan Ahmad ◽  
Pavel Singh ◽  
Chandi Prasad Bhatt ◽  
Irfan Bashir
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Volumetric Modulated Arc Therapy ◽  
Neck Region ◽  
Complete Response ◽  
Final Diagnosis ◽  
Small Cell ◽  
Response To Treatment ◽  
Curative Intent ◽  
Aggressive Approach

Extrapulmonary small cell carcinomas (EPSCC) are a rare subtype of neuroendocrine tumours which have been documented to arise from a multitude of sites and treatment outcomes are disappointing. The most common site involved in the head and neck region is the larynx and the oropharynx as a primary site has been infrequently reported. The patient presented with bilateral neck swelling and an ulcerated lesion was noted in the base of tongue (BOT). A biopsy revealed small cell carcinoma (SCC) and was confirmed with immunohistochemistry. The final diagnosis after workup was SCC of BOT stage IVc. He received induction chemotherapy to which the tumour responded partially, followed by curative intent chemoradiotherapy and adjuvant chemotherapy. The patient achieved a radiological complete response to treatment and almost all treatment-induced toxicities resolved. An aggressive approach to managing EPSCC is possible with modern radiotherapy techniques, with tolerable treatment-induced toxicities.

Changes to levels of serum neuron-specific enolase in a patient with small cell carcinoma of the pancreas

2005 ◽  
Vol 12 (1) ◽  
pp. 93-98 ◽  
Author(s):  
Yoshiharu Nakamura ◽  
Takashi Tajiri ◽  
Eiji Uchida ◽  
Yasuo Arima ◽  
Takayuki Aimoto ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuron Specific Enolase ◽  
Small Cell ◽  
Carcinoma Of The Pancreas ◽  
Serum Neuron Specific Enolase

Long-Term Outcomes of Organ Preservation in Patients with Small Cell Carcinoma of the Bladder

2015 ◽  
Vol 94 (4) ◽  
pp. 401-405 ◽  
Author(s):  
Jairam R. Eswara ◽  
Niall M. Heney ◽  
Chin-Lee Wu ◽  
W. Scott McDougal
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Metastatic Disease ◽  
Advanced Disease ◽  
Chemical Exposure ◽  
Small Cell ◽  
Cancer Specific Survival ◽  
Entire Cohort ◽  
Aggressive Disease ◽  
Carcinoma Of The Bladder

Background: Small cell carcinoma of the bladder is an uncommon but clinically aggressive disease. There is no standard surgical or medical management for the disease. Methods: Between 1995 and 2009, 28 patients underwent transurethral resection (TUR) and/or cystectomy, chemotherapy, and/or radiation for small cell carcinoma of the bladder at our institution. Results: The median follow-up for survivors was 34 months. Patients presented most often with muscle-invasive disease (T2-4 - 89%), and 21% had lymph node/distant metastases. Tobacco use and chemical exposure were noted in 64 and 4% of patients, respectively. Patients with T1-2N0M0 had a median survival of 22 months compared to 8 months for those with more advanced disease (p = 0.03). Patients with T3-4 or nodal/metastatic disease who were given chemotherapy had an improved survival compared to those with T3-4 or nodal/metastatic disease who did not undergo chemotherapy (13 vs. 4 months, p = 0.005). The median time to recurrence of the entire cohort was 8 months, overall and cancer-specific survival was 14 months, and 5-year survival was 11%. Conclusions: Small cell carcinoma of the bladder is an aggressive disease with poor outcomes. Patients with T1-2N0M0 disease survived longer than those with advanced disease. Patients with T3-4 or nodal/metastatic disease had improved survival with chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document